Evidence map›Paper›PMID 42274331›Full record

Trial reportHuman vaccines & immunotherapeutics2026

Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.

Andrew Hastie, Vinay Gupta, Patricia Lese, Jaynier Moya, Sonia Schoonbroodt, Serge Beudjekian, Frank Struyf

Abstract readRandomized Controlled TrialClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew HastieGSK, Rockville, MD, USA.
Vinay GuptaGSK, Bangalore, India.
Patricia LeseGSK, Rockville, MD, USA.
Jaynier MoyaPines Care Research Center, Hollywood, FL, USA.
Sonia SchoonbroodtGSK, Rixensart, Belgium.
Serge BeudjekianGSK, Mississauga, ON, Canada.
Frank StruyfGSK, Wavre, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza pandemics arise from novel influenza A viruses. Recent emergence of a new clade (2.3.4.4.b) of the highly pathogenic H5N1 in animals and humans highlighted its pandemic potential. We evaluated the immunogenicity and safety of GSK's AS03-adjuvanted H5N8 vaccine in adults. In this phase 1/2, observer-blinded, age-stratified, randomized trial, healthy US adults (age, ≥18 y) received two intramuscular doses of hemagglutinin antigen (3.75 or 7.50 μg) with AS03

Indexed as

Adjuvants, Immunologicalpha-TocopherolImmunogenicity, VaccineInfluenza, HumanInfluenza VaccinesPolysorbatesSqualeneAdolescentAdultAgedAntibodies, ViralDrug CombinationsDrug-Related Side Effects and Adverse ReactionsFemaleHemagglutination Inhibition TestsHumansAdjuvants, Immunologicalpha-TocopherolAntibodies, ViralAS03 adjuvantDrug CombinationsInfluenza VaccinesPolysorbatesSqualeneA/AstrakhanadultsAS03AAS03BH5N8 subtypeimmunogenicityinfluenzainfluenza vaccines

Identifiers

PMID42274331
PMCPMC13271333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.